Key Highlights

  • Apimeds Pharmaceuticals US reduced its issued and outstanding common stock from 15,091,180 shares to 1,509,118 shares through a reverse stock split.
  • The company lowered common stock Par Value from USD 0.01 per share to USD 0.001 per share, while authorized common stock of 100,000,000 shares and authorized preferred stock of 10,000,000 shares remained unchanged.
  • Split-adjusted trading began under new CUSIP 03771D201, and no fractional shares were issued.
  • The number of common shares underlying outstanding Equity awards and warrants, along with their exercise prices, received proportionate adjustments.

Reverse Split Resets Share Count and Par Value

Apimeds Pharmaceuticals US, a biotechnology company, reduced its issued and outstanding common stock from 15,091,180 shares to 1,509,118 shares through a reverse stock split, while its authorized share pools remained unchanged at 100,000,000 common shares and 10,000,000 preferred shares. The company also lowered common stock par value from USD 0.01 per share to USD 0.001 per share. Apimeds Pharmaceuticals US submitted the related certificate of amendment to Delaware authorities on July 23, 2026, and no fractional shares were issued in connection with the split.

New CUSIP Marks Split-Adjusted Trading

The post-split common stock began trading under a new CUSIP, 03771D201, marking the shift to a split-adjusted basis. The authorized common-stock amount remains 100,000,000 shares and authorized preferred stock remains 10,000,000 shares, so the changes affected the issued and outstanding share count and identifier rather than the company's authorized capital structure.

Equity Awards and Warrants Adjusted Proportionately

The number of common shares underlying Apimeds Pharmaceuticals US's outstanding equity awards and warrants received proportionate adjustments to reflect the reverse split, and the exercise prices attached to those awards and warrants were adjusted at the same time, keeping the economic terms of existing instruments consistent with the new share count.

Where Things Stand

With the reverse split completed, the par value reduced and equity awards, warrants and the CUSIP all adjusted, the near-term focus shifts to how the stock trades on its new split-adjusted share count under CUSIP 03771D201.